Why I’m One of the First Physicians to Partner With Astron Health — and What This Means for My Patients

MedLogic Medicine and Dr. Jennifer Ron, MD, FACEP, ABOIM are bringing precision oncology and integrative cancer care together for patients in Chicagoland.

Patients typically arrive in our office with two things: a treatment plan from their oncologist, and a deep, unwavering motivation to use every available tool to heal to keep cancer from taking control of their lives.

That's exactly why Dr. Ron partnered with Astron Health and incorporated the Polaris Report into her integrative cancer care practice.

The Polaris Report is a precision oncology tool that translates a patient's molecular profile (analyzed against over 170,000 peer-reviewed studies) into a ranked, evidence-scored set of treatment options, expanding far beyond what conventional oncology typically surfaces.

Here's why that matters and what it could mean for you.

Why Most Molecular Testing Results Go Unused

Today, nearly half of all cancer patients in the U.S. undergo some form of molecular testing.

Yet only about 13% receive a therapy matched to what that testing reveals.

That means the vast majority of valuable molecular data that could influence treatment decisions is sitting unused.

The Polaris Report is designed to close that gap.

By expanding the therapeutic lens to include repurposed medications, evidence-based supplements, and lifestyle interventions alongside conventional therapies, the proportion of actionable targets rises dramatically; often reaching 80–85%.

Why Cancer Care Needs a Wider Lens

For much of the last century, cancer research has moved between two dominant theories: that cancer is fundamentally a genetic disease, or that it is primarily driven by metabolic and environmental factors.

The Cancer Genome Atlas was expected to settle the debate. Instead, it revealed something far more complex; profound heterogeneity, with a patchwork of mutations that defied simple explanations.

This has renewed interest in something earlier researchers like Otto Warburg emphasized nearly a century ago: the importance of terrain, the internal biological environment that can either support or suppress tumor growth.

Genetics absolutely matter. But increasingly, evidence suggests they may represent downstream effects rather than the root cause.

The terrain helps determine whether AND HOW those genetic programs are expressed. This is the lens Dr. Ron brings to every patient she works with in the Chicagoland area and across the country.

What "Terrain-Based Cancer Care" Actually Means for You

“When I talk about ‘terrain’, I'm referring to the internal conditions that influence how cancer behaves and how your body responds to treatment.” – says Dr. Ron.

In her practice, Dr. Ron uses a structured clinical framework to evaluate and optimize key factors, including:

• Inflammation: chronic inflammation can fuel tumor progression

• Immune function: your immune system's ability to recognize and fight cancer cells

• Metabolic health: including blood sugar regulation, which directly affects tumor growth

• The microbiome: gut health influences immunity, inflammation, and treatment response

• Oxygenation and circulation: adequate oxygen delivery supports healing

• Circadian rhythm: disrupted sleep patterns can impair immune surveillance

• Toxic burden: accumulated environmental exposures that stress the body

• Stress response: chronic stress hormones can accelerate disease progression

Each of these plays a direct role in treatment outcomes.

A patient with unmanaged chronic stress, impaired glucose metabolism, or a disrupted circadian rhythm may not respond optimally, even to the most well-designed therapies.

Addressing the terrain isn't an alternative to treatment. It's what allows treatment to work.

Wherever you are in your cancer journey: newly diagnosed, actively in treatment, or navigating survivorship — Dr. Ron meets you there. As a cancer survivor herself, your partner and guide, she aligns what matters most to you with what is uncovered together through your clinical history and data.

How the Polaris Report Expands Your Treatment Options

The Polaris Report bridges the gap between what molecular testing reveals and what you can do with that information.

Each treatment option is ranked by the Astron Evidence Score, a composite score that incorporates clinical trial data, target relevance, drug-target binding confidence, and regulatory status. This means you and your care team aren't sifting through raw data; you're seeing a prioritized, evidence-ranked roadmap.

What This Looks Like in Practice

Consider breast cancer with a high mutation burden.

A conventional molecular report might identify a BRCA1 mutation and recommend a PARP inhibitor. The Polaris Report does that AND then goes further.

It identifies:

• Activated growth pathways (such as mTOR and CDK)

• Tumor survival mechanisms (including BCL2 and survivin)

• Markers of genomic instability (such as TP53 and BRCA1)

From there, it surfaces interventions for each target ranked by evidence score so decisions are both evidence-informed and clinically practical.

For that same patient, the report might highlight:

• Metformin, for its multi-pathway effects in mTOR-altered tumors

• Sirolimus, based on pathway targeting

• Caffeine, supported by emerging clinical data

• Nutraceuticals like Berberine, with evidence for specific molecular targets

Each option is prioritized so we can build a comprehensive, layered strategy; not just rely on a single agent.

The Research That Makes This Real

These aren't theoretical claims. The evidence is already in the literature, it's just difficult for any individual clinician to systematically identify and apply without advanced tools.

Example 1: A Swedish study of over 1,000 women found that ER-positive breast cancer patients on tamoxifen who consumed the highest levels of coffee experienced a 50% reduction in recurrence. A synthetic lethality database helps explain why: combining estrogen receptor inhibition with PIK3CA pathway modulation, a synergy achieved through tamoxifen and caffeine.

Example 2: A randomized trial of 3,649 high-risk breast cancer patients evaluated metformin. Initial results showed no overall benefit. But when researchers analyzed by subtype, HER2-positive patients with a specific genetic variant experienced a 49% improvement in disease-free survival.

These are the kinds of insights that change outcomes. The Polaris Report surfaces them systematically, so nothing gets missed.

Why Precision Oncology and Terrain-Based Care Belong Together

Precision oncology and integrative cancer care are not competing approaches. They are complementary and, in our practice, they are inseparable.

• Molecular data tells us what is happening inside the tumor

• Terrain assessment tells us what is happening within the patient

The Polaris Report translates molecular data into actionable strategies. A terrain-based approach ensures those strategies can work in the body they're applied to.

Even the most precisely targeted therapy will only perform as well as the biological environment allows.

Integration is where real clinical power lies.

What This Means for You

If you've already had molecular testing, there is likely more actionable information in your results than you've been told.

If you haven't, it may be worth exploring.

Either way, the goal remains the same: to put cancer in the back seat.

You are the driver. Cancer is an uninvited passenger. Dr. Ron’s role, using both the precision of the Polaris Report and a personalized, terrain-based approach is to help you navigate with confidence.

Ready To Explore What's Possible?

If you're a cancer patient in the Chicagoland area looking for an integrative oncology approach that uses the latest in precision medicine, or if you've had molecular testing and want to know what else your results can tell you — Let’s Talk! Schedule a complimentary 15-min consultation.

If you're a clinician interested in integrating the Polaris Report into your practice, Dr. Jennifer Ron is happy to share what she has learned. Let's connect.